A randomised clinical trial of docetaxel and estrogen in patients with castration resistant prostate cancer

INTERVENTION: Chemotherapy: Docetaxel 70mg/m2 div. every 4 weeks. Predonisolone 10mg/day p.o. daily. Hormonal therapy: Ethynil estradiol 1.0mg/day p.o. daily. CONDITION: Castration‐resistant prostate cancer PRIMARY OUTCOME: Time to treatment failure INCLUSION CRITERIA: 1) Patients diagnosed as prostate cancer pathologically at the initial treatment. 2)Clinical any T any N any M prostate cancer patient treated by androgen deprivation therapy prior to this trial. 3)Cancer relapse or disease progression must be confirmed after androgen deprivation therapy. 4)Age over 20 years old 5)4) Patients must be at a score level of 0‐1 of performance status (PS) (ECOG). 6)Major organ function must be conserved before registration. 7)Written informed consent must be obtained from patients.